US Stock MarketDetailed Quotes
ACAD ACADIA Pharmaceuticals
- 16.710
- +0.400+2.45%
Close Apr 26 16:00 ET
2.76BMarket Cap-45162P/E (TTM)
16.740High16.265Low1.17MVolume16.450Open16.310Pre Close19.39MTurnover1.06%Turnover RatioLossP/E (Static)165.20MShares33.99052wk High6.39P/B1.84BFloat Cap16.16052wk Low--Dividend TTM110.30MShs Float58.720Historical High--Div YieldTTM2.91%Amplitude0.650Historical Low16.594Avg Price1Lot Size
ACADIA Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 114.65%16.7M | 457.97%85.39M | -8,009.35%-58.96M | 162.48%8.2M | 76.51%-17.93M | 9.25%-114.04M | -3.17%-23.85M | 95.74%-727K | 48.18%-13.13M | -26.90%-76.33M |
| Net income from continuing operations | 71.62%-61.29M | 209.76%45.8M | -139.77%-65.18M | 103.28%1.11M | 61.95%-43.02M | -28.66%-215.98M | 3.18%-41.73M | -88.03%-27.18M | 22.47%-34.01M | -70.14%-113.06M |
| Operating gains losses | -29.45%-4.59M | --0 | 30.94%-1.49M | 150.30%1.24M | -1,180.24%-4.34M | -52.08%-3.54M | 4.87%-1.54M | -462.92%-2.16M | 379.21%497K | -133.79%-339K |
| Depreciation and amortization | 174.04%5.55M | 234.76%1.64M | 240.51%1.72M | 242.91%1.77M | -17.44%426K | -39.41%2.03M | -8.60%489K | -48.63%506K | -44.56%515K | -42.35%516K |
| Change In working capital | -52.27%18.13M | 228.66%21.71M | -196.11%-10.56M | -1,198.92%-9.59M | -21.65%16.56M | 253.04%37.99M | -12.43%6.61M | 156.77%10.98M | 84.29%-738K | 353.96%21.14M |
| -Change in receivables | -1,834.54%-39.27M | -12.59%-7.82M | -181.36%-10.38M | -157.19%-13.91M | -485.07%-7.17M | 115.03%2.26M | -88.90%-6.94M | 229.50%12.75M | -197.07%-5.41M | 126.20%1.86M |
| -Change in inventory | -1,292.88%-28.81M | -4,960.32%-15.07M | -1,853.44%-11.22M | -574.68%-3M | -42.26%481K | 157.36%2.42M | 42.86%310K | 118.03%640K | 263.73%632K | 269.31%833K |
| -Change in prepaid assets | -809.42%-17.69M | -171.54%-1.14M | -588.63%-14.06M | -105.48%-263K | -19.91%-2.23M | 38.40%2.49M | 118.49%1.6M | -228.85%-2.04M | 108.01%4.8M | 33.96%-1.86M |
| -Change in payables and accrued expense | 224.65%97.97M | 367.66%43.37M | 2,431.65%21.66M | 316.74%3.75M | 23.86%29.19M | 399.60%30.18M | 16.51%9.27M | 87.22%-929K | 87.52%-1.73M | 655.98%23.56M |
| -Change in other current assets | -12.00%5.74M | -57.06%739K | 5.05%1.71M | -5.21%1.56M | 13.40%1.73M | 3.51%6.52M | 15.35%1.72M | 7.83%1.63M | -2.88%1.65M | -4.82%1.52M |
| -Change in other current liabilities | 103.42%201K | 150.69%1.63M | 262.35%1.73M | 431.14%2.27M | -13.54%-5.43M | -64.18%-5.88M | -20.80%651K | 39.73%-1.07M | -4,460.00%-684K | -82.44%-4.78M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 114.65%16.7M | 457.97%85.39M | -8,009.35%-58.96M | 162.48%8.2M | 76.51%-17.93M | 9.25%-114.04M | -3.17%-23.85M | 95.74%-727K | 48.18%-13.13M | -26.90%-76.33M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -56.31%32M | 98.04%-347K | 120.91%34.11M | -248.20%-194.28M | 46.57%192.52M | 203.01%73.24M | -124.81%-17.75M | 109.88%15.44M | -224.27%-55.8M | 325.38%131.35M |
| Net PPE purchase and sale | ---50K | --0 | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Net intangibles purchase and sale | ---40M | --0 | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Net investment purchase and sale | -1.63%72.05M | 98.04%-347K | 121.23%34.16M | -176.51%-154.28M | 46.57%192.52M | 204.66%73.24M | -124.81%-17.75M | 109.88%15.44M | -225.12%-55.8M | 311.06%131.35M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -56.31%32M | 98.04%-347K | 120.91%34.11M | -248.20%-194.28M | 46.57%192.52M | 203.01%73.24M | -124.81%-17.75M | 109.88%15.44M | -224.27%-55.8M | 325.38%131.35M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 206.49%25.13M | 236.68%5.43M | 4,342.86%12.75M | 42.99%5.48M | -40.58%1.47M | -54.86%8.2M | -63.02%1.61M | -73.08%287K | -23.46%3.83M | -68.07%2.47M |
| Net common stock issuance | 206.49%25.13M | 236.68%5.43M | 4,342.86%12.75M | 42.99%5.48M | -40.58%1.47M | -54.86%8.2M | -63.02%1.61M | -73.08%287K | -23.46%3.83M | -68.07%2.47M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 206.49%25.13M | 236.68%5.43M | 4,342.86%12.75M | 42.99%5.48M | -40.58%1.47M | -54.86%8.2M | -63.02%1.61M | -73.08%287K | -23.46%3.83M | -68.07%2.47M |
| Net cash flow | ||||||||||
| Beginning cash position | -21.27%120.62M | -35.27%103.96M | -20.29%116.06M | 40.81%296.67M | -21.27%120.62M | -53.83%153.21M | 59.96%160.61M | -46.61%145.6M | -32.09%210.69M | -53.83%153.21M |
| Current changes in cash | 326.50%73.83M | 326.26%90.48M | -180.62%-12.09M | -177.46%-180.6M | 206.27%176.05M | 81.75%-32.6M | -175.74%-39.99M | 108.71%15M | -73.44%-65.09M | 366.79%57.48M |
| Effect of exchange rate changes | -400.00%-18K | -50.00%-12K | -150.00%-4K | --0 | -200.00%-2K | -14.29%6K | -900.00%-8K | 166.67%8K | 300.00%4K | -60.00%2K |
| End cash Position | 61.20%194.43M | 61.20%194.43M | -35.27%103.96M | -20.29%116.06M | 40.81%296.67M | -21.27%120.62M | -21.27%120.62M | 59.96%160.61M | -46.61%145.6M | -32.09%210.69M |
| Free cash flow | 79.53%-23.35M | 457.97%85.39M | -8,016.23%-59.01M | -142.28%-31.8M | 76.51%-17.93M | 10.05%-114.04M | -3.17%-23.85M | 95.74%-727K | 48.27%-13.13M | -24.67%-76.33M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg